U.S. Next-Generation Sequencing (NGS) Services Market (2017-2022)
The U.S. Next-Generation Sequencing (NGS) Services Market was valued at $437.6 Million in 2017 and projected to reach to $1149.2 Million by 2022, representing a compound annual growth rate of 21.3%. The U.S.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
U.S. Next-Generation Sequencing (NGS) Services Market Trends and Insights
- Next-Generation Sequencing (NGS) Services Market demonstrated robust expansion between 2017 and 2022, growing from $437.6 million in 2017 to a forecasted $1,149.2 million by 2022.
- This represents a compound annual growth rate of 21.3%, significantly outpacing broader healthcare technology adoption trends.
- The U.S.
- market benefits from advanced healthcare infrastructure, substantial R&D investment, and widespread adoption of genomic medicine across clinical and research settings. Driving this expansion, the U.S.
- has emerged as a leader in precision medicine initiatives and personalized treatment strategies.
- The U.S.
- market is supported by increasing demand for cancer genomics, rare disease diagnosis, and pharmacogenomics applications.
- By 2022, the U.S.
- NGS services sector is expected to capture a substantial share of North American sequencing activity, reflecting the region's commitment to genomic innovation and clinical implementation of sequencing technologies..
Key Market Statistics
- CAGR (2017-2022) 21.3% CAGR
- Market Size, 2017 ~USD 437.6 Million
- Forecast, 2022 ~USD 1149.2 Million
- Country U.S.
U.S. Next-Generation Sequencing (NGS) Services Market Overview
Exceptional Growth Trajectory :
The U.S. NGS Services Market surged from $437.6 million in 2017 to $1,149.2 million by 2022, representing a 21.3% CAGR that outpaces global growth of 21%, demonstrating the U.S. market's accelerated adoption and investment in sequencing technologies.
Advanced Healthcare Infrastructure :
The U.S. benefits from world-leading diagnostic laboratories, academic medical centers, and clinical research institutions that drive demand for NGS services across oncology, rare disease diagnosis, and personalized medicine applications.
Substantial R&D Investment :
American biotech companies, pharmaceutical firms, and research institutions allocate significant capital to NGS-based drug development and precision medicine initiatives, creating sustained demand for sequencing service providers.
Regulatory Support & Reimbursement :
FDA approvals of NGS-based companion diagnostics and expanding Medicare/insurance coverage for genetic testing have accelerated clinical adoption across U.S. healthcare systems and private diagnostic laboratories.
U.S. Next-Generation Sequencing (NGS) Services Market Dynamics
- NGS Services Market is positioned for continued expansion driven by increasing adoption of precision medicine, growing prevalence of cancer diagnoses requiring genomic profiling, and expanding clinical applications beyond oncology into cardiology and infectious disease.
- Healthcare providers are increasingly integrating NGS into standard diagnostic protocols, supported by improving cost-per-genome economics and broader insurance reimbursement policies. Key growth catalysts include rising demand from pharmaceutical companies conducting genomic biomarker research, expansion of liquid biopsy applications, and integration of NGS into routine clinical workflows.
- The competitive landscape will intensify as established diagnostic companies and emerging biotech firms invest in NGS infrastructure, while consolidation among service providers continues to reshape market dynamics through 2025 and beyond..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- The U.S. NGS services market is projected to grow from $437.6M (2017) to $1,149.2M (2022), representing a 21.3% CAGR.
- The U.S. leads in precision medicine adoption, driving demand for cancer genomics and rare disease diagnostics.
- The U.S. market benefits from advanced healthcare infrastructure and substantial genomic research investment.
- The U.S. NGS services sector is expected to dominate North American sequencing activity by 2022.
Next-Generation Sequencing (NGS) Services Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2017 |
| Fastest Growing Segment | AGRICULTURE & ANIMAL RESEARCH (Application) |
| Forecast Period | 2017–2022 |
| Growth Rate | CAGR of 21% from 2017 to 2022 |
| Largest Segment | DIAGNOSTICS (Application) |
| Market Size Base Year (Billions) | ~USD 1.06 (2017) |
| Revenue Forecast (Billions) | ~USD 2.748 (2022) |
| Segments Covered | Type, Application, End User, Technology |
U.S. Next-Generation Sequencing (NGS) Services Market Report Segmentation
4 segment dimensions are covered across the global market.
By Type
- Chip-Seq
- De Novo Sequencing
- Exome Sequencing
- Methyl-Seq
- Other Ngs Services
- Other Services
- Rna-Seq
- Targeted Sequencing/Custom Gene Panels
- Targeted Sequencing/Gene Panels
- Whole-Genome Sequencing
By Application
- Agriculture & Animal Research
- Biomarker Discovery
- Diagnostics
- Drug Discovery
- Infectious Diseases
- Oncology
- Other Applications
- Other Applications*
- Other Diagnostic Applications
- Rare Genetic Disorders
- Reproductive Health
By End User
- Academic & Government
- Academic & Government Institutes And Research Centers
- Hospitals & Clinics
- Other End Users
- Other End Users*
- Pharmaceutical & Biotechnology Companies
By Technology
- Ion Semiconductor Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis
- Single-Molecule Real-Time Sequencing
Target Audience
- Diagnostic Laboratory Operators : Clinical and reference labs need U.S. market data to assess competitive positioning, identify growth opportunities in NGS service expansion, and benchmark pricing against regional competitors.
- Pharmaceutical & Biotech Companies : Drug developers require insights into U.S. NGS service availability, capacity, and capabilities to plan clinical trial strategies, companion diagnostic development, and genomic biomarker research programs.
- Healthcare System Executives : Hospital networks and integrated delivery systems need market intelligence to evaluate NGS service partnerships, assess build-vs-buy decisions, and plan precision medicine program investments.
- Medical Device & Equipment Manufacturers : NGS platform and reagent providers require U.S. market sizing and adoption trends to forecast demand, identify customer segments, and develop targeted sales strategies for American laboratories.
- Investment & Private Equity Firms : Investors evaluating NGS service companies need U.S. market growth projections, competitive dynamics, and reimbursement trends to assess investment returns and portfolio company valuations.
Key Companies in the U.S. Next-Generation Sequencing (NGS) Services Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ILLUMINA, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| PERKINELMER, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| EUROFINS SCIENTIFIC SE | Luxembourg | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| MACROGEN, INC. | South Korea | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| QIAGEN N.V. | Netherlands | Public Company | Targeted sequencing services (panels, amplicon, gene panels),RNA-Seq services,Exome and de novo sequencing services, |
| DNA LINK, INC. | South Korea | Public Company | Whole genome & De Novo sequencing services,Whole exome & targeted sequencing services,Transcriptome & single-cell RNA sequencing, |
| TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.) | Japan | ||
| NOVOGENE CORPORATION | China | Public Company | Whole genome and targeted sequencing services (incl. human/animal/plant/microbial WGS and targeted panels),Transcriptomics and single-cell sequencing (mRNA, lncRNA, small RNA, single-cell, spatial),De novo, metagenomics, and microbiome sequencing, |
| PERSONALIS, INC. | United States | Public Company | Oncology MRD and monitoring (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling (ImmunoID NeXT, NeXT Dx),Population and research sequencing (WES/WGS services), |
ILLUMINA, INC.
Illumina, Inc. is a public company founded in 1998 and headquartered in the United States with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.
PERKINELMER, INC.
PerkinElmer, Inc. is a public company founded in 1937 and based in the United States with 11,000 employees. The company provides diagnostic and research solutions across life sciences and environmental testing.
EUROFINS SCIENTIFIC SE
Eurofins Scientific SE is a public company founded in 1987 and headquartered in Luxembourg with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.
MACROGEN, INC.
Macrogen, Inc. is a public company founded in 2000 and based in South Korea with 293 employees. The company provides genomic research services including DNA sequencing and analysis.
QIAGEN N.V.
QIAGEN N.V. is a public company founded in 1984 and headquartered in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences tools.
DNA LINK, INC.
DNA Link, Inc. is a public company founded in 2000 and based in South Korea with 84 employees. The company offers genomic analysis and genetic testing services.
TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.)
Takara Bio Inc. is a company based in Japan and operates as part of Takara Holding Company Inc. The company specializes in biotechnology and life sciences research products.
NOVOGENE CORPORATION
Novogene Corporation is a public company founded in 2011 and based in China with 2,225 employees. The company provides genomic sequencing and bioinformatics analysis services.
PERSONALIS, INC.
Personalis, Inc. is a public company founded in 2011 and based in the United States with 260 employees. The company develops genomic testing and analysis solutions for precision medicine.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise U.S. market valuation ($437.6M to $1,149.2M) and 21.3% CAGR data to benchmark competitive positioning, justify investment decisions, and forecast revenue opportunities in the American NGS services sector.
- Regional Competitive Intelligence : Understand U.S.-specific market dynamics, key players, pricing strategies, and competitive advantages unique to American healthcare infrastructure, enabling targeted go-to-market strategies and partnership identification.
- Clinical Adoption Insights : Access detailed analysis of NGS adoption rates across U.S. hospitals, diagnostic labs, and research institutions, identifying high-growth clinical segments and reimbursement trends driving market expansion.
- Regulatory & Reimbursement Landscape : Gain comprehensive understanding of FDA approval pathways, Medicare coverage policies, and insurance reimbursement mechanisms specific to U.S. NGS services, critical for market entry and revenue forecasting.
- Strategic Investment Planning : Leverage U.S. market projections and growth drivers to inform M&A strategies, capital allocation decisions, facility expansion plans, and technology investments in the American NGS services ecosystem.
Frequently asked questions
What was the U.S. NGS services market size in 2017?
The U.S. NGS services market was valued at $437.6 million in 2017.
What is the projected U.S. NGS services market size by 2022?
The U.S. NGS services market is forecasted to reach $1,149.2 million by 2022.
What is the CAGR for the U.S. NGS services market?
The U.S. NGS services market is expected to grow at a compound annual growth rate of 21.3% between 2017 and 2022.
What are the primary drivers of growth in the U.S. NGS services market?
The U.S. market is driven by increasing adoption of precision medicine, rising demand for cancer genomics, rare disease diagnosis, and pharmacogenomics applications.
Why is the U.S. a leader in the NGS services market?
The U.S. leads due to advanced healthcare infrastructure, substantial R&D investment, widespread genomic medicine adoption, and strong precision medicine initiatives.
RESEARCH METHODOLOGY
Get the Full Next-Generation Sequencing (NGS) Services Market Report
Full forecast, segment splits, and company analysis for all Next-Generation Sequencing (NGS) Services Market.
- Canada Next-Generation Sequencing (NGS) Services Market
- Germany Next-Generation Sequencing (NGS) Services Market
- France Next-Generation Sequencing (NGS) Services Market
- China Next-Generation Sequencing (NGS) Services Market
- Japan Next-Generation Sequencing (NGS) Services Market
- India Next-Generation Sequencing (NGS) Services Market
- Roe Next-Generation Sequencing (NGS) Services Market
- U.K. Next-Generation Sequencing (NGS) Services Market
- Roapac Next-Generation Sequencing (NGS) Services Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
